Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at the 2017 Annual Meeting of the Society for Neuro-Oncology
Call to feature key neuro-oncology thought leaders
View HTML
Toggle Summary ZIOPHARM to Present at the Stifel 2017 Healthcare Conference
BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017 at 11:00 a.m. ET.
View HTML
Toggle Summary ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities
Company to host conference call today at 4:30 p.m. ET Pivotal, randomized control trial in rGBM to initiate by end of 2017 Combination trial with checkpoint inhibitor in rGBM to initiate by end of 2017 Point-of-care trial with CAR + T cells co-expressing membrane-bound interleukin (mbIL15) to
View HTML
Toggle Summary ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-Oncology
- Update to survival data from Phase 1 Trial of Ad-RTS-hIL-12 to treat recurrent glioblastoma (GBM) to be presented - - Additional biomarker and biopsy data provides evidence of IL-12 driving immune response to GBM - BOSTON, Nov. 06, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc.
View HTML
Toggle Summary ZIOPHARM Announces Five Abstracts Accepted for Presentation at the 2017 American Society of Hematology Annual Meeting
BOSTON, Nov. 01, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on developing gene and cell-based immunotherapies for cancer, today announced that five abstracts highlighting data from the Company's adoptive cell-based therapeutic programs have
View HTML
Toggle Summary ZIOPHARM Oncology to Host Third-Quarter 2017 Financial Results and Corporate Update Conference Call on November 6, 2017 at 4:30 p.m. ET
BOSTON, Oct. 26, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced that it will host a conference call and webcast slide presentation on Monday, November 6, 2017 at 4:30 p.m.
View HTML
Toggle Summary A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children
  ZIOPHARM Oncology is pleased to share a story from the Ann & Robert H. Lurie Children's Hospital in Chicago on the Ad-RTS-hIL-12 plus veledimex clinical trial for pediatric patients with brain cancer. As we announced last week, Stewart Goldman, M.D., Division Head Hematology-Oncology,
View HTML
Toggle Summary ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors
BOSTON, Oct. 16, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced that the first patient has been dosed in a new Phase 1 study of Ad-RTS-hIL-12 with veledimex for the treatment
View HTML
Toggle Summary ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology
BOSTON, Oct. 12, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on developing gene and cell-based immunotherapies for cancer, today announced that three abstracts highlighting data from the Company's Ad-RTS-hIL-12 + veledimex program have been
View HTML
Toggle Summary ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer
BOSTON, Sept. 28, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focusing on new immunotherapies, announces the appointment of David Mauney, M.D., as Executive Vice President and Chief Business Officer, effective today.  ZIOPHARM also reports the details
View HTML